JCXH-212
/ Immorna
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 17, 2024
A phase I study of a common neoantigen srRNA vaccine (JCXH-212) with or without toripalimab in patients with non-small cell lung cancer(NSCLC)
(ESMO Asia 2024)
- P1 | "Conclusions JCXH-212 monotherapy or in combination with toripalimab demonstrated a tolerable safety profile and induced neoantigen-specific T cell immune responses in patients with advanced NSCLC. Further investigation of JCXH-212 in combination with toripalimab may be conducted in NSCLC."
Clinical • P1 data • Tumor-specific neoantigens • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • IFNG
May 14, 2024
Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Peking University Cancer Hospital & Institute | Trial completion date: Apr 2024 ➔ Apr 2027 | Trial primary completion date: Jan 2024 ➔ Apr 2026
Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
April 10, 2023
Evaluate the Safety and Tolerability of JCXH-212 Injection in the Treatment of Advanced Malignant Solid Tumors
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Peking University Cancer Hospital & Institute | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Oncology • Solid Tumor
October 13, 2022
A Study to Evaluate the Safety and Tolerability of JCXH-212 Injection in the Treatment of Advanced Malignant Solid Tumors
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Peking University Cancer Hospital & Institute
New P1 trial • Oncology • Solid Tumor
1 to 4
Of
4
Go to page
1